There is an important mismatch existing between the types of treatments proposed by patients and clinicians and those being researched.
There is an important mismatch existing between the types of treatments proposed by patients and clinicians and those being researched, according to a study published in Research Involvement and Engagement.
Although the mismatch between clinicians’ and patients’ priorities and researchers’ was first identified 15 years ago, British researchers studying treatment research priorities generated by Priority Setting Partnerships (PSPs) at the James Lind Alliance determined there is still a marked difference.
Lead author Sally Crowe and colleagues assembled priority lists from all the PSPs, totaling 149 priorities in a diverse array of health problems, including asthma, prostate cancer, type 1 diabetes, life after stroke, tinnitus, lyme disease, and pressure ulcers. They then compared the prioritized treatments with those being studied in samples of clinical trials done over the same period of time.
“If research is to reflect the priorities of patients and clinicians, leadership and incentives will be needed,” the authors wrote. “The current research ‘system’ and culture is not geared to bridging the mismatch we have documented.”
On average, drug trials are preferred by researchers, while patients, carers, and clinicians showed a preference for non-drug treatments. Drugs accounted for only 18% of treatments mentioned in priorities for the PSPs, while they accounted for 37% in registered non-commercial trials and 86% in registered commercial trials.
While the researchers were unsurprised that such a high proportion of registered commercial trials concerned the evaluation of drugs, they through it was noteworthy that only 2.6% of these trials studied the effects of non-drug treatments that patients and clinicians rate as being important.
“[The finding] suggests that few of these drug trials can have used non-drug comparators, for example, comparing drugs with psychological therapies for treating depression,” the authors wrote.
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Gene Therapy Success in UK Likely Depends on Overcoming Education, Psychological Support Challenges
November 27th 2023Education, psychological support, and implementation guidance are the top unmet needs identified by investigators from the United Kingdom concerning gene therapy use for hemophilia.
Read More
A Look at Racial Disparities in US HPV Vaccine Uptake
March 1st 2022On this episode of Managed Care Cast, Leslie Cofie, PhD, MPH, an assistant professor of health education and promotion at the College of Health and Human Performance, East Carolina University, discusses his work on identifying and addressing racial disparities in human papillomavirus (HPV) vaccine uptake in the United States.
Listen